• 1
    Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand 1988; 78: 369380.
  • 2
    Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 1999; 5: 293296.
  • 3
    Mayr WT, Pittock SJ, McClelland RL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61: 13731377.
  • 4
    Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932936.
  • 5
    Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53: 17111718.
  • 6
    Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol Scand 1995; 161(suppl): 2333.
  • 7
    Compston A, Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep 2002; 2: 259266.
  • 8
    Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47: 425448.
  • 9
    Dean G. Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. BMJ 1967; 2: 724730.
  • 10
    Kurtzke JF, Dean G, Botha DPJ. A method for estimating the age at immigration of white immigrants to South Africa, with an example of its importance. S Afr Med J 1970; 44: 663669.
  • 11
    Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000; 123: 968974.
  • 12
    Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 1966; 15: 234237.
  • 13
    Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978; 28: 10891093.
  • 14
    Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 1985; 35: 672678.
  • 15
    Dean G, McLoughlin H, Brady R, et al. Multiple sclerosis among immigrants in Greater London. BMJ 1976; 1: 861864.
  • 16
    Dean G, Brady R, McLoughlin H, et al. Motor neurone disease and multiple sclerosis among immigrants to Britain. Br J Prev Soc Med 1977; 31: 141147.
  • 17
    Elian M, Dean G. Motor neuron disease and multiple sclerosis among immigrants to England from the Indian subcontinent, the Caribbean, and East and West Africa. J Neurol Neurosurg Psychiatry 1993; 56: 454457.
  • 18
    Elian M, Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J Neurol Neurosurg Psychiatry 1987; 50: 327332.
  • 19
    Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry 1990; 53: 906911.
  • 20
    Kurtzke JF. Multiple sclerosis among immigrants. BMJ 1976; 1: 15271528.
  • 21
    Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004; 55: 6571.
  • 22
    Pugliatti M, Sotgiu S, Solinas G, et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001; 103: 2026.
  • 23
    Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195202.
  • 24
    Poskanzer DC, Walker AM, Yonkondy J, Sheridan JL. Studies in the epidemiology of multiple sclerosis in the Orkney and Shetland Islands. Neurology 1976; 26: 1417.
  • 25
    Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6: 382427.
  • 26
    Leibowitz U, Antonovsky A, Medalie JM, et al. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966; 29: 6068.
  • 27
    Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911920.
  • 28
    Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest 1999; 104: 527529.
  • 29
    Hunter SF, Hafler DA. Ubiquitous pathogens: links between infection and autoimmunity in MS? Neurology 2000; 55: 164165.
  • 30
    Beebe GW, Kurtzke JF, Kurland LT, et al. Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the Army experience in World War II. Neurology 1967; 17: 117.
  • 31
    Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. Neurology 1997; 48: 204213.
  • 32
    Russell WR. Multiple sclerosis: occupation and social group at onset. Lancet 1971; 2: 832834.
  • 33
    Granieri E, Casetta I. Part III: selected reviews. Common childhood and adolescent infections and multiple sclerosis. Neurology 1997; 49(suppl 2): S42S54.
  • 34
    Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293: 463469.
  • 35
    Like AA, Guberski DL, Butler L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes 1991; 40: 259262.
  • 36
    Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981; 2: 1290.
  • 37
    Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 1980; 37: 9496.
  • 38
    Bray PF, Bloomer LC, Salmon VC, et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983; 40: 406408.
  • 39
    Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435438.
  • 40
    Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985; 17: 371377.
  • 41
    Shirodaria PV, Haire M, Fleming E, et al. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol 1987; 44: 12371241.
  • 42
    Ferrante P, Castellani P, Barbi M, Bergamini F. The Italian Cooperative Multiple Sclerosis case-control study: preliminary results on viral antibodies. Ital J Neurol Sci 1987;(suppl 6): 4550.
  • 43
    Munch M, Hvas J, Christensen T, et al. The implications of Epstein-Barr virus in multiple sclerosis—a review. Acta Neurol Scand 1997; 169(suppl): 5964.
  • 44
    Myhr K-M, Riise T, Barrett-Connor E, et al. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psychiatry 1998; 64: 539542.
  • 45
    Wagner HJ, Hennig H, Jabs WJ, et al. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol 2000; 13: 497502.
  • 46
    Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 30833088.
  • 47
    Haahr S, Plesner AM, Vestergaard BF, Hollsberg P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2004; 109: 270275.
  • 48
    Sundström P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62: 22772282.
  • 49
    Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11: 220224.
  • 50
    Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004; 291: 18751879.
  • 51
    Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67: 20632065.
  • 52
    Benensen AS, ed. Control of communicable diseases in man. 15th ed. Washington, DC: American Public Health Association, 1990: 509.
  • 53
    Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481492.
  • 54
    Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59: 499503.
  • 55
    Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996: 23972446.
  • 56
    Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55: 178184.
  • 57
    Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health 2004; 58: 10321035.
  • 58
    Haire M, Fraser KB, Millar JHD. Virus-specific immunoglobulins in multiple sclerosis. Clin Exp Immunol 1973; 14: 409416.
  • 59
    Clarke JK, Dane DS, Dick GW. Viral antibody in the cerebrospinal fluid and serum of multiple sclerosis patients. Brain 1965; 88: 953962.
  • 60
    Panelius M, Salmi AA, Halonen P, Penttinen K. Measles antibodies detected with various techniques in sera of patients with multiple sclerosis. Acta Neurol Scand 1971; 47: 315330.
  • 61
    Poskanzer DC, Sever JL, Sheridan JL, Prenney LB. Multiple sclerosis in the Orkney and Shetland Islands. IV: Viral antibody titres and viral infections. J Epidemiol Community Health 1980; 34: 258264.
  • 62
    Leinikki P, Shekarchi I, Iivanainen M, et al. Virus antibodies in the cerebrospinal fluid of multiple sclerosis patients detected with ELISA tests. J Neurol Sci 1982; 57: 249255.
  • 63
    Krakowka S, Miele JA, Mathes LE, Metzler AE. Antibody responses to measles virus and canine distemper virus in multiple sclerosis. Ann Neurol 1983; 14: 533538.
  • 64
    Hawkes CH, Giovannoni G, Keir G, et al. Seroprevalence of herpes simplex virus type 2 in multiple sclerosis. Acta Neurol Scand 2006; 114: 363367.
  • 65
    Lennette ET, Rymo L, Yadav M, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993; 29A: 15841589.
  • 66
    Kusunoki Y, Huang H, Fukuda Y, et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol 1993; 37: 461469.
  • 67
    de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274: 756761.
  • 68
    Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320: 689695.
  • 69
    de-Thé G. Epidemiology of Epstein-Barr virus and associated diseases in man. In: Roizman B, ed. The herpesviruses. Vol. 1. New York: Plenum Press, 1982: 25103.
  • 70
    Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese Men. N Engl J Med 2001; 345: 18771882.
  • 71
    Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 24962500.
  • 72
    DeLorenze GN, Munger KL, Lennette E, et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63: 839844.
  • 73
    Henle W, Henle G, Niederman JC, et al. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis. J Infect Dis 1971; 124: 5867.
  • 74
    Horwitz CA, Henle W, Henle G, et al. Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis 1985; 151: 11501153.
  • 75
    Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006; 129: 14931506.
  • 76
    Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2: 417426.
  • 77
    Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in asymptomatic carriers. J Virol 2003; 77: 18401847.
  • 78
    Niederman JC, Evans AS. Epstein-Barr virus. In: Evans AS, Kaslow RA, eds. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical Book Company, 1997: 253283.
  • 79
    Heath CW Jr, Brodsky AL, Potolsky AI. Infectious mononucleosis in a general population. Am J Epidemiol 1972; 95: 4652.
  • 80
    Brodsky AL, Heath CW Jr. Infectious mononucleosis: epidemiologic patterns at United States colleges and universities. Am J Epidemiol 1972; 96: 8793.
  • 81
    Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979; 29: 12281235.
  • 82
    Chang RS, Char DFB, Jones JH, Halstead SB. Incidence of infectious mononucleosis at the Universities of California and Hawaii. J Infect Dis 1979; 140: 479486.
  • 83
    Melbye M, Ebbesen P, Bennike T. Infectious mononucleosis in Greenland: a disease of the non-indigenous population. Scand J Infect Dis 1984; 16: 915.
  • 84
    Chan WW. Eskimos and multiple sclerosis (Letter). Lancet 1977; 1: 1370.
  • 85
    Henle W, Henle G. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. The Epstein Barr virus. Berlin Heidelberg New York: Springer; 1979: 6178.
  • 86
    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S1688S.
  • 87
    Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 1984; 312: 449450.
  • 88
    Cuomo L, Angeloni A, Zompetta C, et al. Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism. AIDS Res Hum Retroviruses 1995; 11: 12411245.
  • 89
    Alvarez-Lafuente R, De Las Heras V, Bartolome M, et al. Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study. Brain Pathol 2006; 16: 2027.
  • 90
    Derfuss T, Hohlfeld R, Meinl E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol 2005; 252: 968971.
  • 91
    Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995; 67: 197255.
  • 92
    Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 17651777.
  • 93
    Munch M, Hvas J, Christensen T, et al. A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. Acta Neurol Scand 1998; 98: 395399.
  • 94
    Kurtzke JF, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J Clin Epidemiol 2001; 54: 122.
  • 95
    Poser CM, Hiberd PL, Benedikz J, Gudmundsson G. Analysis of the ‘epidemic’ of multiple sclerosis in the Faroe Islands. Neuroepidemiology 1988; 7: 168180.
  • 96
    Poser CM, Hibberd PL. Analysis of the ‘epidemic’ of multiple sclerosis in the Faroe Islands. II. Biostatistical aspects. Neuroepidemiology 1988; 7: 181189.
  • 97
    Dean G. Was there an epidemic of multiple sclerosis in the Faroe Islands? Neuroepidemiology 1988; 7: 165167.
  • 98
    Ashitey GA, Mackenzie G. ‘Clustering’ of multiple sclerosis cases by date and place of birth. Br J Prev Soc Med 1970; 24: 163168.
  • 99
    Hargreaves ER, Merrington M. A note on the absence of ‘clustering’ of multiple sclerosis cases. J Chronic Dis 1973; 26: 4750.
  • 100
    Neutel CI, Walter SD, Mousseau G. Clustering during childhood of multiple sclerosis patients. J Chronic Dis 1977; 30: 217224.
  • 101
    Poskanzer DC, Walker AM, Prenney LB, Sheridan JL. The etiology of multiple sclerosis: temporal-spatial clustering indicating two environmental exposures before onset. Neurology 1981; 31: 708713.
  • 102
    Riise T, Grønning M, Klauber MR, et al. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol 1991; 133: 932939.
  • 103
    Pugliatti M, Riise T, Sotgiu MA, et al. Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian population. Am J Epidemiol 2006; 164: 326333.
  • 104
    Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. III. An alternative assessment of the three epidemics. Acta Neurol Scand 1987; 76: 317339.
  • 105
    Nye FJ, Spicer CC. Space-time clustering in infectious mononucleosis. Br J Prev Soc Med 1972; 26: 257258.
  • 106
    Hilton DA, Love S, Fletcher A, Pringle JH. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry 1994; 57: 975976.
  • 107
    Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2: 249258.
  • 108
    Cook SD. Does Epstein-Barr virus cause multiple sclerosis? Rev Neurol Dis 2004; 1: 115123.
  • 109
    Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940943.
  • 110
    Hollsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132: 137143.
  • 111
    Holmoy T, Vartdal F. Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol 2004; 10: 5256.
  • 112
    Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 2000; 173: 3239.
  • 113
    Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115: 13521360.
  • 114
    Sutkowski N, Palkama T, Ciurli C, et al. An Epstein-Barr virus-associated superantigen. J Exp Med 1996; 184: 971980.
  • 115
    van Sechel AC, Bajramovic JJ, van Stipdonk MJ, et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999; 162: 129135.
  • 116
    Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24: 584588.
  • 117
    Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707717.
  • 118
    Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 8094.
  • 119
    James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001; 44: 11221126.
  • 120
    Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998; 50: 571572.
  • 121
    Munger KL, DeLorenze GN, Levin LI, et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 2004; 62: 17991803.
  • 122
    Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult Scler 2006; 12: 397411.
  • 123
    Knox KK, Brewer JH, Henry JM, et al. Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. Clin Infect Dis 2000; 31: 894903.
  • 124
    Boman J, Roblin PM, Sundstrom P, et al. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000; 54: 265.
  • 125
    Kaufman M, Gaydos CA, Sriram S, et al. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002; 8: 289294.
  • 126
    Fotheringham J, Jacobson S. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 2005; 12: 49.
  • 127
    Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev 1997; 10: 521567.
  • 128
    Opsahl ML, Kennedy PG. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005; 128: 516527.
  • 129
    Cermelli C, Berti R, Soldan SS, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 2003; 187: 13771387.
  • 130
    Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995; 92: 74407444.
  • 131
    Soldan SS, Jacobson S. Role of viruses in etiology and pathogenesis of multiple sclerosis. Adv Virus Res 2001; 56: 517555.
  • 132
    Soldan SS, Berti R, Salem N, et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997; 3: 13941397.
  • 133
    Ablashi DV, Eastman HB, Owen CB, et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000; 16: 179191.
  • 134
    Akhyani N, Berti R, Brennan MB, et al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 2000; 182: 13211325.
  • 135
    Xu Y, Linde A, Fredrikson S, et al. HHV-6 A- or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum. J Med Virol 2002; 66: 394399.